Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas.
Tabor J, O'Brien J, Vasandani S, Vetsa S, Lei H, Jalal M, Marianayagam N, Jin L, Millares Chavez M, Haynes J, Dincer A, Yalcin K, Aguilera S, Omay S, Mishra-Gorur K, McGuone D, Morales-Valero S, Fulbright R, Gunel M, Erson-Omay E, Moliterno J. Clinical and genomic differences in supratentorial versus infratentorial NF2 mutant meningiomas. Journal Of Neurosurgery 2023, 139: 1648-1656. PMID: 37243548, DOI: 10.3171/2023.4.jns222929.Peer-Reviewed Original ResearchConceptsSubtotal resectionSupratentorial tumorsElevated Ki-67High-risk featuresProgression-free survivalChromosome 1p deletionInfratentorial counterpartsInfratentorial tumorsPostoperative managementSomatic driver mutationsCerebral convexityGrade IIInfratentorial meningiomasKi-67Posterior fossaLoss of heterozygosityMeningiomasResectionTumorsWhole-exome sequencing dataDriver mutationsHigh gradeSignificant differencesExome sequencing dataSporadic meningiomasSurgical strategies for intracranial meningioma in the molecular era
Dincer A, Morales-Valero S, Robert S, Tabor J, O’Brien J, Yalcin K, Fulbright R, Erson-Omay Z, Dunn I, Moliterno J. Surgical strategies for intracranial meningioma in the molecular era. Journal Of Neuro-Oncology 2023, 162: 253-265. PMID: 37010677, PMCID: PMC10167142, DOI: 10.1007/s11060-023-04272-z.Peer-Reviewed Original ResearchConceptsExtent of resectionGrade 1 tumorsInfluence of surgeryTreatment of choiceHigh recurrence rateBiology of meningiomasIntroductionSurgical resectionSymptomatic recurrenceDisease recurrenceDefinitive managementRecurrence rateSurgical strategyWHO gradeIntracranial meningiomasClinical predictive powerMalignant transformationGrading scaleNatural historyMeningiomasUnexpected recurrenceRecurrence